top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ:WGS)

102.00 +0.65 (+0.64%)
Streaming Delayed Price Updated: 9:38 AM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeneDx Holdings Corp. - Class A Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025
From GeneDx
Via Business Wire
News headline image
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication
From GeneDx
Via Business Wire
News headline image
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
News headline image
Unlocking the high Growth Potential of GENEDX HOLDINGS CORP (NASDAQ:WGS). ↗
Exploring high growth characteristics of GENEDX HOLDINGS CORP (NASDAQ:WGS). A fundamental and technical analysis of (NASDAQ:WGS). 
Via Chartmill
News headline image
Does GENEDX HOLDINGS CORP (NASDAQ:WGS) align with Mark Minervini’s trading strategy? ↗
A fundamental and technical analysis of (NASDAQ:WGS): Why the high growth investor may take a look at GENEDX HOLDINGS CORP (NASDAQ:WGS). 
Via Chartmill
News headline image
Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
From GeneDx
Via Business Wire
News headline image
GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting
From GeneDx
Via Business Wire
News headline image
GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis
From GeneDx
Via Business Wire
News headline image
SPY Trying To Find A Floor At The 200 SMA; One New Swing ↗
In this video lesson I review the day-one of a new rally attempt in the overall market, discuss my new swing trade in a cyber-security leader, and review my tier-one long-term portfolio purchases in my... 
Via Talk Markets
Topics Stocks / Equities
News headline image
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
From GeneDx
Via Business Wire
News headline image
Powerful UnR Session As All Four Market Indices Lockstep Rally Into The Close; Bear Trap Set? ↗
In this video lesson, I review the overall market, the recent bearish sentiment, and one new swing trade idea for Monday's session. 
Via Talk Markets
Topics Stocks / Equities
News headline image
Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
From GeneDx
Via Business Wire
News headline image
Top Biotech GeneDx Catapults 42% After Obliterating Earnings Forecasts ↗
GeneDx stock catapulted more than 40% on Tuesday after the top-notch biotech smashed fourth-quarter expectations. 
Via Investor's Business Daily
News headline image
Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings ↗
 
Via Benzinga
News headline image
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday? ↗
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
From GeneDx
Via Business Wire
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 18, 2025 ↗
 
Via Benzinga
News headline image
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
From GeneDx
Via Business Wire
News headline image
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
From GeneDx
Via Business Wire
News headline image
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
From GeneDx
Via Business Wire
News headline image
GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
From GeneDx
Via Business Wire
News headline image
GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play
Saying shares of GeneDx skyrocketed in 2024 may be an understatement. As a leader in its market, upside is still a legitimate possibility for this name. 
Via MarketBeat
News headline image
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
News headline image
Stocks Moving Lower Despite Encouraging Inflation Data ↗
Via Talk Markets
Topics Economy Stocks / Equities
News headline image
GeneDx Announces Preliminary 2024 Financial Results
From GeneDx
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page